In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
Best practices for grounding brand decision-making in insights
In today’s evolving pharmaceutical landscape, harnessing the power of insights is more critical than ever. Integrating primary, secondary, and analytical...